A Phase 2 interventional study of ATX101 and bupivacaine hydrochloride in Total Knee Arthroplasty (Postoperative Pain), sponsored by Allay Therapeutics, Inc.. Completed at 11 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Allay Therapeutics, Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 1,180 studies in Pain, Postoperative with a site in United States — 203 open to participants now, 236 under way, 25 of them phase 3. Pain, Postoperative · United States.
Among the 1,180 studies in Pain, Postoperative with a site in United States, this one is the 141st largest by enrollment of the 1,098 interventional ones that give a count, is one of 49 that started in 2025, is one of 121 in phase 2, and was the 1,074th registered.
5,654 studies on the registry are indexed under Pain, Postoperative; 1,233 are open to participants now.
Browse Pain, Postoperative studies →203 of the 1,180 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:
Loma Linda University · Sites in United States
Ages 18+ · Men only
Columbia University · Sites in United States
Ages 12–21
Duke University · Sites in United States
Ages 18+ · Healthy volunteers
Stanford University · Sites in United States
Ages 18+ · Women only
Hospital for Special Surgery, New York · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 676 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 327 (48%) stop at 75 or younger; 74 take children under 18; 128 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
1,180 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 66 · Phase 2 155 · Phase 3 179 · Phase 4 359
First in 1996; this study’s year is marked. 49 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 226 is above the median of 75 across 4,835 interventional studies indexed under Pain, Postoperative.
Median enrollment 76 across the 1,098 interventional studies, 130 across the 82 observational. Of the 784 that completed or were terminated, 474 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
199 of 1,180 have an industry lead sponsor. The 10 most frequent:
Allay Therapeutics, Inc. is the lead sponsor of 2 studies on the registry; none are open to participants now.
Allay Therapeutics, Inc. has 2 studies filed under Pain, Postoperative — fewer than ten, so there is no comparison to draw.
97 of the studies in Pain, Postoperative with a site in United States that are under way reach primary completion within a year, 13 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07060495Phase 3Rutgers, The State University of New JerseyRADA16 for Adult Tonsillectomy | 2026-12-01 |
| NCT07539623Phase 3Icahn School of Medicine at Mount SinaiSuzetrigine-enhanced MultimOdal Opioid-sparing THerapy in Cardiac and Bariatric SURGery | 2026-12-22 |
| NCT07226076Phase 3Medical University of South CarolinaMethadone in TKA for Post-op Pain and Opioid Reduction | 2026-12-28 |
| NCT07565870Phase 3Alexandre P. JoostenMethadone for Enhanced Postoperative Analgesia in Intermediate-Risk Noncardiac Surgery (MELODY) | 2026-12-31 |
| NCT05058287Phase 3Hospital for Special Surgery, New YorkLumbar Steroid Use in Patients Undergoing Posterior Lumbar Decompression | 2026-12-31 |
Add all 97 to your calendar (.ics) → With an account.
Among the 1,180 studies in Pain, Postoperative with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of the ATX101-TKA-004 clinical trial aims to evaluate the efficacy and safety of ATX101 1,500 mg in participants undergoing primary unilateral total knee arthroplasty. The study will compare the effectiveness of ATX101 with a saline placebo and bupivacaine, an active comparator. Additionally, it will assess opioid consumption among participants receiving ATX101 versus those given the saline placebo and bupivacaine. The trial will also focus on the safety and tolerability of ATX101 in the participants.
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol defined Inclusion/Exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: ATX101
Drug: saline placebo
Drug: bupivacaine hydrochloride
ATX101 bupivacaine implants, total of 1,500 mg into the surgical site
bupivacaine hydrochloride 0.25% without epinephrine/adrenaline, total 125 mg in 50 mL via local periarticular infiltration
normal saline (0.9%) sodium chloride, total volume of up to 17 mL via local periarticular infiltration
Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: from 30 minutes through 168 hours (Day 8)
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: From 30 minutes through 336 hours (Day 15)
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: From 30 minutes through 504 hours (Day 22)
Total Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo
Total post-surgical consumption of rescue opioid medications in morphine milligrams equivalent (MME) dose from 30 minutes through 336 hours (Day 15)
Time frame: From 30 minutes through 336 hours (Day 15)
AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: From 30 minutes through 336 hours (Day 15)
Difference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo
The NRS with activity (NRS-A) for pain intensity is an 11-item scale from 0 to 10 where participants rank the level of pain intensity after an activity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
Time frame: Day 15
| Milestone | ATX101 | Saline Placebo | Bupivacaine Hydrochloride |
|---|---|---|---|
| Started | 92 | 93 | 46 |
| Enrolled | 89 | 93 | 44 |
| Completed | 87 | 90 | 42 |
| Not completed | 5 | 3 | 4 |
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| score on a scale*hours | ATX101 | Saline Placebo |
|---|---|---|
| Area Under the Curve (AUC) for the Numerical Rating Scale at Rest (NRS-R) of Pain Intensity From 30 Minutes Through 168 Hours (Day 8) Compared to Placebo | 980.61 ± 280.748 | 985.19 ± 264.943 |
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| score on a scale*hours | ATX101 | Saline Placebo |
|---|---|---|
| AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo | 1811.50 ± 572.586 | 1812.66 ± 547.247 |
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| score on a scale*hours | ATX101 | Saline Placebo |
|---|---|---|
| AUC for the NRS-R of Pain Intensity From 30 Minutes Through 504 Hours (Day 22) Compared to Placebo | 2545.41 ± 875.961 | 2536.75 ± 843.180 |
Total post-surgical consumption of rescue opioid medications in morphine milligrams equivalent (MME) dose from 30 minutes through 336 hours (Day 15)
| Morphine Milligram Equivalents | ATX101 | Saline Placebo |
|---|---|---|
| Total Post-surgical Consumption of Opioid Medications From 30 Minutes Through 336 Hours (Day 15) Compared to Placebo | 233.416 ± 208.8313 | 229.261 ± 187.0728 |
Numeric Rating Scale at Rest (NRS-R) for Pain Intensity is an 11-item scale from 0 to10 where participants rank the level of pain intensity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| score on a scale*hours | ATX101 | Bupivacaine Hydrochloride |
|---|---|---|
| AUC for the NRS-R of Pain Intensity From 30 Minutes Through 336 Hours (Day 15) Compared to Active Comparator | 1811.50 ± 572.586 | 1852.07 ± 610.273 |
The NRS with activity (NRS-A) for pain intensity is an 11-item scale from 0 to 10 where participants rank the level of pain intensity after an activity. The NRS scale goes from No Pain (0) to Worst Imaginable Pain (10).
| score on a scale | ATX101 | Saline Placebo |
|---|---|---|
| Difference in NRS-A Pain Intensity Scores During the Timed Up and Go (TUG) Test at Day 15 Compared to Placebo | 3.4 ± 2.10 | 3.6 ± 2.06 |
Collected over Day 45. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| ATX101 | 0/90 (0%) | 9/90 (10%) | 71/90 (78.9%) |
| Saline Placebo | 0/92 (0%) | 5/92 (5.4%) | 81/92 (88%) |
| Bupivacaine Hydrochloride | 0/44 (0%) | 1/44 (2.3%) | 35/44 (79.5%) |
| Event | ATX101 | Saline Placebo | Bupivacaine Hydrochloride |
|---|---|---|---|
| Heart rate increasedInvestigations | 0/90 | 0/92 | 1/44 |
| Respiratory rate increasedInvestigations | 0/90 | 0/92 | 1/44 |
| Liver function test increasedInvestigations | 2/90 | 0/92 | 0/44 |
| Muscle spasmsMusculoskeletal and connective tissue disorders | 1/90 | 0/92 | 0/44 |
| Hepatitis AInfections and infestations | 1/90 | 0/92 | 0/44 |
| Pilonidal diseaseInfections and infestations | 1/90 | 0/92 | 0/44 |
| Deep vein thrombosisVascular disorders | 1/90 | 0/92 | 0/44 |
| Orthostatic hypotensionVascular disorders | 1/90 | 0/92 | 0/44 |
| ConstipationGastrointestinal disorders | 1/90 | 0/92 | 0/44 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 1/90 | 0/92 | 0/44 |
| Event | ATX101 | Saline Placebo | Bupivacaine Hydrochloride |
|---|---|---|---|
| NauseaGastrointestinal disorders | 27/90 | 34/92 | 13/44 |
| VomitingGastrointestinal disorders | 10/90 | 16/92 | 2/44 |
| ConstipationGastrointestinal disorders | 15/90 | 10/92 | 7/44 |
| DizzinessNervous system disorders | 9/90 | 9/92 | 6/44 |
| Blood pressure increasedInvestigations | 10/90 | 9/92 | 5/44 |
| Blood pressure decreasedInvestigations | 2/90 | 7/92 | 4/44 |
| HeadacheNervous system disorders | 8/90 | 8/92 | 3/44 |
| Gamma-glutamyltransferase increasedInvestigations | 8/90 | 4/92 | 2/44 |
| Liver function test increasedInvestigations | 8/90 | 4/92 | 0/44 |
| HypoxiaRespiratory, thoracic and mediastinal disorders | 3/90 | 8/92 | 3/44 |
Full Analysis Set (FAS)
| Age, Categorical(Participants) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 58 | 60 | 32 | 150 |
| >=65 years | 31 | 33 | 12 | 76 |
| Age, Continuous(years) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| Mean | 61.2 ± 8.74 | 61.0 ± 8.23 | 61.8 ± 8.12 | 61.3 ± 8.38 |
| Sex: Female, Male(Participants) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| Female | 46 | 56 | 21 | 123 |
| Male | 43 | 37 | 23 | 103 |
| Race (NIH/OMB)(Participants) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 1 | 0 | 0 | 1 |
| Black or African American | 16 | 12 | 10 | 38 |
| White | 71 | 78 | 33 | 182 |
| More than one race | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 1 | 3 | 0 | 4 |
| Region of Enrollment(participants) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| United States | 89 | 93 | 44 | 226 |
| Body Mass Index(kg/m2)(kg/m^2) | ATX101 | Saline Placebo | Bupivacaine Hydrochloride | Total |
|---|---|---|---|---|
| Mean | 33.465 ± 5.7841 | 33.900 ± 5.0824 | 34.346 ± 5.5547 | 33.816 ± 5.4452 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Feb 2025 to primary completion in Oct 2025, 8 months.
Results were first posted in Oct 2026, 1 year after primary completion.
Of 49 industry-sponsored phase 2 interventional studies under Pain, Postoperative, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 11. This study's 8 months is above that.
Counting every sponsor, half of 139 studies reached it within 12 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: APIM-containing Peptide ATX-101
Allay Therapeutics, Inc.